GIC Re enters top 10 list of global reinsurers
GIC Re enters top 10 list of global reinsurers

GIC Re enters top 10 list of global reinsurers

Dnyanada Kulkarni Article rating: 4.8

GIC Re has emerged as the 10th largest amongst the top 40 Global Reinsurers, as reported by Standard and Poor’s. The ranking is based on the net premium booked by the reinsurer in 2018. GIC Re demonstrated 24.5 per cent growth in its top line during FY 2018, while amassing a staggering premium of Rs. 41,799 crore.

All you need to know about International Mutual Funds
All you need to know about International Mutual Funds

All you need to know about International Mutual Funds

Henil Shah Article rating: 4.5

The advantages of diversification is a much talked topic in the investor community. Diversification is one of the key tools for mitigating risk. Diversification means investing in unrelated asset classes. Investors may also further diversify their portfolio by spreading risk across geographies.

Government bans sale of 328 fixed-dose combinations
Government bans sale of 328 fixed-dose combinations

Government bans sale of 328 fixed-dose combinations

Gayathri Udyawar Article rating: 5.0

Health Ministry has prohibited the manufacture and sale of 328 fixed-dose combinations (FDCs) for human use with immediate effect observing that they may involve risk to patients.

Wipro partners with Duck Creek Technologies
Wipro partners with Duck Creek Technologies

Wipro partners with Duck Creek Technologies

Dnyanada Kulkarni Article rating: 3.1

Soap-to-software company Wipro gained after the company announced a partnership with Duck Creek Technologies, developer of software for property and casualty insurers across the globe. The partnership arrangement is such that Wipro will provide a multitude of implementation services and associated software and data solutions to insurance companies. 

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

Shital Jibhe Article rating: 5.0

The markets on September 12, 2018 opened up. BSE Sensex is trading at 37,377.19, down by 35.94 points and the Nifty is trading at 11,264.25, down by 23.25 points. 

Sun Pharma falls as USFDA investigates Mohali plant
Sun Pharma falls as USFDA investigates Mohali plant

Sun Pharma falls as USFDA investigates Mohali plant

Dnyanada Kulkarni Article rating: 4.3

Sun Pharma’s Mohali plant in Punjab is undergoing a three-day surprise investigation by the USFDA. The investigation commenced on September 10, 2018, confirmed the company in an exchange filing. The company is of the opinion that the investigation will not cause any material impact.

RSS
First28612862286328642866286828692870Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR